FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

yf_tkr_JNJ · 2026-08-24 · Bullish AI sentiment

$JNJ

Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. The approval, which follows FDA Priority Review, marks the first time a therapy was proven safe and effective specifically for the treatment of wA

Read the original at yf_tkr_JNJ ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.